PDF(Sci-hub)
Abstract：
UNASSIGNED: To assess the efficacy and safety of a treatment regimen based on rectal administration of Boswellia resin extract and propolis derived polyphenols in patients with type IIIa and type IIIb chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS).
UNASSIGNED: Patients with type IIIa and type IIIb CP/CPPS received one rectal suppository a day for 15 days per month for 3 consecutive months. Participants were evaluated with National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI), the International Prostate Symptom Scores (IPSS), International Index of Erectile Function (IIEF), four-glass test, uroflowmetry, and prostate-specific antigen assessments at baseline and at Week 4, and Week 12. Primary endpoints were improvement in pain domain of NIH-CPSI and improvement of NIH-CPSI total score. Secondary outcomes included improvement of micturition and quality of life (QoL) domains of NIH-CPSI questionnaire.
UNASSIGNED: A total of 61 males were enrolled. No adverse events were reported. Significant improvements from baseline to Day 30 were reported for NIH-CPSI total score (mean difference: -9.2; p<0.01), NIH-CPSI pain domain (mean difference: -5.5; p<0.01), NIH-CPSI micturition domain, NIH-CPSI QoL domain, and IPSS total score (mean difference: -5.6; p<0.01). No significant changes from baseline in terms of IIEF score or maximum flow rate were observed. At final follow-up (Day 90), further significant improvements in terms of NIH-CPSI total score (mean difference: -12.2; p<0.01), NIH-CPSI pain domain (mean difference: -6.6; p<0.01), NIH-CPSI micturition domain, NIH-CPSI QoL domain, and IPSS total score were reported.
UNASSIGNED: Rectal administration of Boswellia resin extract and propolis derived polyphenols is well tolerated and delivers a significant symptomatic improvement in most patients with type IIIa and type IIIb CP/CPPS.
UNASSIGNED: Patients with type IIIa and type IIIb CP/CPPS received one rectal suppository a day for 15 days per month for 3 consecutive months. Participants were evaluated with National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI), the International Prostate Symptom Scores (IPSS), International Index of Erectile Function (IIEF), four-glass test, uroflowmetry, and prostate-specific antigen assessments at baseline and at Week 4, and Week 12. Primary endpoints were improvement in pain domain of NIH-CPSI and improvement of NIH-CPSI total score. Secondary outcomes included improvement of micturition and quality of life (QoL) domains of NIH-CPSI questionnaire.
UNASSIGNED: A total of 61 males were enrolled. No adverse events were reported. Significant improvements from baseline to Day 30 were reported for NIH-CPSI total score (mean difference: -9.2; p<0.01), NIH-CPSI pain domain (mean difference: -5.5; p<0.01), NIH-CPSI micturition domain, NIH-CPSI QoL domain, and IPSS total score (mean difference: -5.6; p<0.01). No significant changes from baseline in terms of IIEF score or maximum flow rate were observed. At final follow-up (Day 90), further significant improvements in terms of NIH-CPSI total score (mean difference: -12.2; p<0.01), NIH-CPSI pain domain (mean difference: -6.6; p<0.01), NIH-CPSI micturition domain, NIH-CPSI QoL domain, and IPSS total score were reported.
UNASSIGNED: Rectal administration of Boswellia resin extract and propolis derived polyphenols is well tolerated and delivers a significant symptomatic improvement in most patients with type IIIa and type IIIb CP/CPPS.
摘要：
UNASSIGNED：评估基于直肠给药Boswellia树脂提取物和蜂胶衍生多酚的治疗方案在IIIa型和IIIb型慢性前列腺炎和慢性盆腔疼痛综合征（CP/CPPS）患者中的疗效和安全性。
UNASSIGNED：IIIa型和IIIb型CP/CPPS患者每天接受一次直肠栓剂，每月15天，连续3个月。参与者采用美国国立卫生研究院慢性前列腺炎症状指数（NIH-CPSI）进行评估，国际前列腺症状评分（IPSS），国际勃起功能指数(IIEF)，四玻璃测试，尿流仪,和在基线和第4周和第12周的前列腺特异性抗原评估。主要终点是NIH-CPSI疼痛领域的改善和NIH-CPSI总分的改善。次要结果包括NIH-CPSI问卷的排尿和生活质量（QoL）领域的改善。
未经评估：共招募了61名男性。未报告不良事件。据报道，NIH-CPSI总分从基线到第30天的显着改善（平均差：-9.2；p<0.01），NIH-CPSI疼痛域（平均差：-5.5；p<0.01），NIH-CPSI排尿域,NIH-CPSIQoL域，和IPSS总分（平均差：-5.6；p<0.01）。在IIEF评分或最大流速方面没有观察到相对于基线的显著变化。在最后的随访（第90天），在NIH-CPSI总分方面进一步显着改善（平均差：-12.2；p<0.01），NIH-CPSI疼痛域（平均差：-6.6；p<0.01），NIH-CPSI排尿域,NIH-CPSIQoL域，报告IPSS总分。
UNASSIGNED：在大多数IIIa型和IIIb型CP/CPPS患者中，Boswellia树脂提取物和蜂胶衍生的多酚的直肠给药耐受性良好，症状明显改善。
UNASSIGNED：IIIa型和IIIb型CP/CPPS患者每天接受一次直肠栓剂，每月15天，连续3个月。参与者采用美国国立卫生研究院慢性前列腺炎症状指数（NIH-CPSI）进行评估，国际前列腺症状评分（IPSS），国际勃起功能指数(IIEF)，四玻璃测试，尿流仪,和在基线和第4周和第12周的前列腺特异性抗原评估。主要终点是NIH-CPSI疼痛领域的改善和NIH-CPSI总分的改善。次要结果包括NIH-CPSI问卷的排尿和生活质量（QoL）领域的改善。
未经评估：共招募了61名男性。未报告不良事件。据报道，NIH-CPSI总分从基线到第30天的显着改善（平均差：-9.2；p<0.01），NIH-CPSI疼痛域（平均差：-5.5；p<0.01），NIH-CPSI排尿域,NIH-CPSIQoL域，和IPSS总分（平均差：-5.6；p<0.01）。在IIEF评分或最大流速方面没有观察到相对于基线的显著变化。在最后的随访（第90天），在NIH-CPSI总分方面进一步显着改善（平均差：-12.2；p<0.01），NIH-CPSI疼痛域（平均差：-6.6；p<0.01），NIH-CPSI排尿域,NIH-CPSIQoL域，报告IPSS总分。
UNASSIGNED：在大多数IIIa型和IIIb型CP/CPPS患者中，Boswellia树脂提取物和蜂胶衍生的多酚的直肠给药耐受性良好，症状明显改善。
